Nothing Special   »   [go: up one dir, main page]

EP2652123B1 - Dry granulated cell culture media - Google Patents

Dry granulated cell culture media Download PDF

Info

Publication number
EP2652123B1
EP2652123B1 EP11788050.0A EP11788050A EP2652123B1 EP 2652123 B1 EP2652123 B1 EP 2652123B1 EP 11788050 A EP11788050 A EP 11788050A EP 2652123 B1 EP2652123 B1 EP 2652123B1
Authority
EP
European Patent Office
Prior art keywords
cell culture
culture medium
components
media
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11788050.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2652123A1 (en
Inventor
Michael Howard Rayner-Brandes
Xiaojian Zhao (David)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45044505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2652123(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP2652123A1 publication Critical patent/EP2652123A1/en
Application granted granted Critical
Publication of EP2652123B1 publication Critical patent/EP2652123B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture

Definitions

  • the present invention relates to dry granulated cell culture media which do not comprise peptones or tryptones, especially to dry granulated cell culture media formulations that support the growth of mammalian, and/or insect and/or plant cells.
  • the present invention further relates to the production of these dry granulated cell culture media and their use.
  • the cell culture media may comprise more than 10, sometimes more than one hundred different components.
  • the culture media required for the propagation of mammalian, insect or plant cells are typically much more complex than the minimal media sufficient to support the growth of bacteria and yeasts.
  • Chemically defined media often comprise but are not exclusively limited to amino acids, vitamins, metal ions, antioxidants, chelators, growth factors, buffers, hormones, chlorides and many more substances known to those expert in the art
  • cell culture media are offered as sterile aqueous liquids.
  • the disadvantage of liquid cell culture media is their reduced shelf life and difficulties for shipping and storage.
  • many cell culture media are presently offered as finely milled dry powder mixtures. They are manufactured for the purpose of dissolving in water and/or aqueous solutions and in the dissolved state are designed, often with other supplements, for supplying biological cells with a substantial nutrient base for growth and/or production of biopharmaceuticals from same said cells.
  • the de-mixing can have effects far beyond physical depletion and concentration of individual components, for example, on target biopharmaceutical molecule production amounts per batch or more subtly on the oligosaccharide patterning on biopharmaceuticals themselves making media quality absolutely critical to biopharmaceutical quality right until the patient.
  • Another aspect when using finely milled dry powder media is the difficulty to dissolve the fine powder in aqueous solutions to prepare the final aqueous cell culture medium. It is very difficult to wet a finely milled powder and dissolve it in an aqueous liquid. Therefore, the handling of the powder media and their use is quite complicated.
  • US2008/0254119 is directed to the production of nutritional supplement tablets or pharmaceutical tablets comprising a lubricant.
  • a roller compactor is mentioned as a suitable instrument for intermediate compaction.
  • powdered bacterial cell culture media can be granulated by pressing the powder to small granules.
  • the result are small particles with advantages in safety, handling and performance.
  • This procedure can be easily realized for bacterial cell culture media as they comprise chemically poorly defined peptones or tryptones or equivalent peptidic components that support the adherence of the media components through their inherent stickiness.
  • Mammalian, and/or insect and/or plant cell culture media typically do not contain peptones or their equivalents and are thus much more difficult to handle in this manner.
  • US 6,383,810 B2 by Invitrogen Corporation discloses a method of producing an agglomerated eukaryotic cell culture medium powder.
  • the method comprises wetting a dry powder cell culture medium with a solvent and then re-drying the moistened medium to obtain a dry agglomerated cell culture medium.
  • peptone free, chemically defined mammalian, and/or insect and/or plant cell culture media can be produced in a dry granulated form by compacting the mixed, finely milled powder of the dry medium components. Compaction is achieved by press agglomeration in role presses. No additives need to be used to aid the process.
  • the dry granulated cell culture media according to the present invention have a long shelf life, are easy to handle and are produced under very mild conditions so that no side reactions occur due to wetting or heating the medium components during the manufacturing process.
  • the present invention is directed to the use of a dry granulated cell culture medium which does not comprise peptones or tryptones for culturing cells according to the present invention by:
  • the cell culture medium that is provided in step a) is a mammalian cell culture medium.
  • the press capacity of the roll press is between 30 and 80 kN/cm roll width.
  • more than 80% of the particles of the granulated cell culture medium have a size larger than 0.5 mm.
  • more than 90% of the particles of the granulated cell culture medium have a size larger than 0.5 mm.
  • the dry granulated cell culture medium which does not comprise peptones or tryptones comprises one or more saccharide components, one or more amino acids, one or more vitamins, one or more salts, one or more buffer components, one or more co-factors and one or more nucleic acid components.
  • the solvent in step a) is water.
  • Figure 1 shows a schematic view of a dry compaction equipment suitable for the present invention.
  • Dry granulation according to the present invention creates granules or particles by compaction of the powders under pressure - without the addition of water or other solvents.
  • the roll press which is used according to the present invention generates also larger compacts or flakes. These compacts so-formed are typically broken up gently, e.g. by a vibrating sieve, to produce granulated particles (agglomerates).
  • a powder or a finely milled powder is a composition of particles of which more than 80% have a particle size (diameter) of less than 0.2 mm.
  • the powder is dry and free-flowing.
  • free flowing powder is meant a powder (made by milling, micropelletizing or similar technique) of which the particles do not adhere to one another. All powders that show an angle of repose below about 50 degrees typically show suitable flow properties but as used herein, the terms dry and free-flowing shall also refer to the gross appearance of the powder - that means the powder looks dry and free-flowing.
  • a cell culture medium according to the present invention is any mixture of components which maintains and/or supports the in vitro growth of cells.
  • the cell culture medium can comprise all components necessary to maintain and/or support the in vitro growth of cells or only some components so that further components are added separately.
  • Examples of cell culture media according to the present invention are full media which comprise all components necessary to maintain and/or support the in vitro growth of cells, media supplements or feeds.
  • the cell culture medium is a full medium.
  • the cell culture media according to the invention are used to maintain and/or support the growth of cells in a bioreactor.
  • a mammalian cell culture medium is a mixture of components which maintain and/or support the in vitro growth of mammalian cells.
  • mammalian cells are human or animal cells, preferably CHO cells, COS cells, I VERO cells, BHK cells, AK-1 cells, SP2/0 cells, L5.1 cells, hybridoma cells or human cells.
  • Cells to be cultured with the media according to the present invention may be normal cells, diseased cells, transformed cells, mutant cells, somatic cells, germ cells, stem cells, precursor cells or embryonic cells, any of which may be established or transformed cell lines or obtained from natural sources.
  • a cell culture medium which does not comprise peptones or tryptones is a cell culture medium which does not contain any peptones or tryptones or other peptides produced by partial hydrolysis of proteins.
  • the cell culture medium which does no comprise peptones or tryptones also does not comprise any proteins or other naturally derived polymers like agar.
  • the cell culture medium which does not comprise peptones or tryptones is a chemically defined cell culture medium.
  • Chemically defined cell culture media are cell culture media which do not comprise any chemically undefined substances. That means the chemical composition and structure of all the chemicals used in the chemically defined media are known.
  • the chemically defined media do not comprise any yeast, animal or plant tissue; they do not comprise feeder cells, serum, extracts or digests or other components which may contribute chemically poorly defined proteins to the media.
  • Chemically undefined or poorly defined chemical structures are those whose chemical composition and structure is not known or could only be defined with enormous experimental effort - comparable to the evaluation of the chemical composition and structure of a protein like albumine or casein.
  • the cell culture medium which does not comprise peptones or tryptones only contains one or more saccharide components, one or more amino acids, one or more vitamins, one or more salts, one or more buffer components, one or more co-factors and one or more nucleic acid components.
  • the size of a particle means the mean diameter of the particle.
  • the particle diameter is determined by laser light scattering in silicone oil.
  • Saccharide components are all mono- or di-saccharides, like glucose, galactose, ribose or fructose (examples of monosaccharides) or sucrose, lactose or maltose (examples of disaccharides).
  • amino acids according to the invention are the proteinogenic amino acids, especially the essential amino acids, leucine, isoleucine, lysine, methionine, phenylalanine, threonine, tryptophane and valine, as well as the non-proteinogenic amino acids like D-amino acids.
  • Vitamin A Retinol, retinal, various retinoids, and four carotenoids
  • Vitamin B 1 Thiamine
  • Vitamin B 2 Rostoflavin
  • Vitamin B 3 Niacin, niacinamide
  • Vitamin B 5 Purothenic acid
  • Vitamin B 6 Pyridoxine, pyridoxamine, pyridoxal
  • Vitamin B 7 Biotin
  • Vitamin B 9 Fluor acid, folinic acid
  • Vitamin B 12 Cyanocobalamin, hydroxycobalamin, methylcobalamin
  • Vitamin C Ascorbic acid
  • Vitamin D Ergocalciferol, cholecalciferol
  • Vitamin E Tocopherols, tocotrienols
  • Vitamin K phytoquinone, menaquinones
  • salts are components comprising inorganic ions such as bicarbonate, calcium, chloride, magnesium, phosphate, potassium and sodium or trace elements such as Co, Cu, F, Fe, Mn, Mo, Ni, Se, Si, Ni, Bi, V and Zn.
  • buffers are CO 2 /HCO 3 , HEPES, PIPES, ACES, BES, TES, MOPS and TRIS.
  • cofactors are thiamine derivatives, biotin, vitamin C, NAD/NADP, cobalamin, flavin mononucleotide and derivatives, glutathione, heme nucleotide phophates and derivatives.
  • Nucleic acid components are the nucleobases, like cytosine, guanine, adenine, thymine or uracil, the nucleosides like cytidine, uridine, adenosine, guanosine and thymidine, and the nucleotides like adenosine monophosphate or adenosine diphosphate or adenosine triphosphate.
  • a stable cell culture medium is a medium which after storage over a certain amount of time shows at least 80% preferably at least 90%, more preferred at least 97%, most preferred the same biological and biochemical activity when compared to a freshly made medium of the same formulation.
  • the present invention is based on the finding that also media which do not comprise peptones or tryptones or similar components can be provided in a dry granulated form. This was very unexpected as up to now only cell culture media with peptones or tryptones could be dry granulated. It was assumed that the adhesive properties of the peptones or tryptones were essential for the production of dry granulated media.
  • the compaction procedure is performed in two basic steps.
  • a finely milled dry powder of the media components is provided. All components are thoroughly mixed so that all parts of the powder mixture have nearly the same composition.
  • the mixture should have the same quality with respect to its uniformity of composition as a commercial dry powder cell culture medium. The higher the uniformity of the composition, the better the quality of the resulting dry granulated medium with respect to homogenous cell growth.
  • Mills which are suitable to produce fine milled powders are for example ball mills, pin mills, jet mills or rotating blade sieve mills.
  • the particle size of the powders is typically below 500 ⁇ m, preferably below 200 ⁇ m.
  • the components can for example be first mixed and then finely milled as a mixture or they can be milled separately or in sub-groups and combined and mixed afterwards.
  • Preferably all components of the mixture are dry. That means, if they comprise water, they do only comprise water of crystallization but not more than 5%, preferably not more than 2% most preferred not more than 1% by weight of unbound or uncoordinated water molecules.
  • the mixing and milling can be performed under an inert protective gas.
  • step b the powder mixture is compacted in a roll press.
  • a roll press also called roller compactor
  • a roll press comprises two counter-rotating rolls which are located at a small distance of about 0.5 to 3 mm, preferably 1 to 2 mm next to each other.
  • Suitable roll presses typically have rolls with a widths between 10 and 50 cm resulting in the gap between the roll having a length between 10 and 50 cm. Nevertheless, the size of the rolls and thus the length of the gap between the rolls can vary depending on the size of the roll press. In a preferred embodiment, the gap has a length between 10 and 15 cm.
  • the mixed powder material is drawn in between the counter-rotating rolls and compacted in the gap between the rolls.
  • the distance between the rolls and their surface structure have influence on the final size and structure of the resulting granulated particles.
  • the surface of the rolls is preferably riffled.
  • the riffles help to make the powder stick to the roll and to pull it through the press.
  • the press capacity of the roll press typically is between 20 and 150 kN/cm roll width, preferably the rolls are pressed together with a force between 30 and 80 kN, most preferred between 40 and 60 kN.
  • the compacting procedure can be performed under an inert protective gas atmosphere.
  • the rolls of the roll press are usually cooled to maintain a constant temperature since often some components are heat-sensitive and would not stand the slightly enlarged temperature which might occur due to compaction.
  • the compacted cell culture medium which is set free from the roll press is directly sized. This can for example be done by sieving, e.g. with one or more vibrating sieves.
  • the diameter of the holes in the sieve depends on the size of the granules to be collected. For the process according to the present invention, a typical diameter is between 0.5 to 5 mm, preferably around 1to 3 mm.
  • a sieve mill is used for granulating the compacts or flakes to granules of suitable size.
  • One suitable sieve mill is the oscillating sieve mill, type FC 200, Bepex GmbH, with a sieve size between 1 and 3 mm.
  • Roll presses which are suitable for the process according to the present invention, can for example be purchased from Alexanderwerk, Sahut Coreur, Hosokawa or Fitzpatrick Company.
  • the size of the particles of the dry granulated cell culture medium depends on the way the compacted medium which comes out of the roll press is treated. If the medium is directly collected from the roll press, it typically comprises larger compacts or flakes. If the medium is sieved, the particle size is determined by the size of the sieve. But also further handling like packaging typically influences the mean particle size as some particles of the granulated cell culture media might break into pieces.
  • more than 80% of the particles of the granulated cell culture medium have a size larger than 0.5 mm.
  • more than 90% of the particles of the granulated cell culture medium have a size larger than 0.5 mm.
  • the quality of the granulated cell culture media can be further improved if the fraction of the compacted media which is set free from the roll press which has particle sizes smaller than 0.5, preferably smaller than 0.2 mm, is continuously reintroduced into the feed of the roll press again to be re-mixed with the powder mixture and to be re-pressed. This reduces the powder fraction of the final dry granulated cell culture medium and additionally improves the homogeneity of the product.
  • FIG. 1 gives a schematic view of one possible production assembly.
  • the roll press is shown as roll R1 and roll R2.
  • the powder mixture P1 is fed from a reservoir into the roll press.
  • the compacted mixture which is set free from the roll press is sized with sieve S.
  • the product fraction is removed for further treatment and packaging, the powder fraction P2 which has a particle size below 0.2 mm is continuously reintroduced into the feed of the roll press.
  • the resulting dry granulated cell culture medium can then be further processed.
  • the medium can be packaged and/or sterilized. Suitable containers are known to a person skilled in the art. Examples are bags, boxes, bottles, cartons, vacuum-packed forms etc.
  • the packaging can be performed prior or after sterilization. Preferred is gamma-irradiation after appropriate packaging.
  • the dry granulated cell culture media can also favourably be used for the production of other compacted media forms like tablets or larger flakes.
  • the dry granulated cell culture media are subjected to further compaction in a suitable press, e.g. a tablet press.
  • the granulated medium can be used as it is without the addition of other components or can be mixed with other components like tabletting aids or mixed or later on coated with components specific for e.g. slow release tablets.
  • the dry granulated cell culture medium can be mixed with components that support the fast dissolution of the tablets, like sodium bicarbonate.
  • the cell culture media which are dry granulated or compacted typically comprise at least one or more saccharide components, one or more amino acids, one or more vitamins or vitamin precursors, one or more salts, one or more buffer components, one or more co-factors and one or more nucleic acid components.
  • the media may also comprise fatty acids and/or fatty acid derivatives and/or pluronic acid and/or surface active components like chemically prepared non-ionic surfactants.
  • a suitable non-ionic surfactant are difunctional block copolymer surfactants terminating in primary hydroxyl groups, e.g. available under the trade name pluronic ® from BASF, Germany.
  • the dry granulated media can be used for the same purposes as the powder media or liquid media known in the art. They can be preferably used in biopharma production as also large amounts of the granulated media can easily be handled without the disadvantages discussed for the powder media.
  • a solvent preferably water (most particularly distilled and/or deionized water or purified water or water for injection) or an aqueous buffer is added to the dry granulated media and the components are mixed until the medium is totally dissolved in the solvent.
  • the solvent may also comprise saline, soluble acid or base ions providing a pH range of 1.0-10. 0, stabilizers, surfactants, preservatives, and alcohols or other polar organic solvents.
  • the dry granulated media are easy to handle. In comparison to powder media, the amount of dust which forms when handling the media is significantly reduced.
  • the media can easily be dissolved in solvents.
  • the reconstitution is rapid, preferably less than 30 minutes, more preferably less than 15 minutes.
  • the composition of the dry granulated media remains homogenous, even in case of shaking or vibration during transport.
  • the milder dry granulation conditions allow for the direct and easy processing of media comprising even heat- and/or oxidation sensitive substances like vitamins (e.g. vitamin B1), glucose, thiamine, iron salts or components comprising disulfide bonds.
  • vitamins e.g. vitamin B1
  • glucose e.g. glucose, thiamine, iron salts or components comprising disulfide bonds.
  • Dulbecco's Modified Eagle Medium also known as DMEM, is a medium often used for growing animal cells.
  • the ingredients of DMEM are in mg/l: inorganic salts: CaCl 2 (waterfree): 200,00 Fe(NO 3 ) ⁇ 9 H 2 O: 0,10 KCl : 400,00 MgSO 4 (waterfree): 97,67 NaCl : 6400,00 NaH 2 PO 4 ⁇ H 2 O: 125,00
  • the resulting material shows a high percentage of larger compacts.
  • the resulting material is sieved in an oscillating sieve mill, type FC 200, Bepex GmbH, with a sieve size of 3 mm.
  • the fraction of granules with a size (diameter) below 0.2 mm are reintroduced into the roll press.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP11788050.0A 2010-12-16 2011-11-18 Dry granulated cell culture media Active EP2652123B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42370010P 2010-12-16 2010-12-16
PCT/EP2011/005830 WO2012079679A1 (en) 2010-12-16 2011-11-18 Dry granulated cell culture media

Publications (2)

Publication Number Publication Date
EP2652123A1 EP2652123A1 (en) 2013-10-23
EP2652123B1 true EP2652123B1 (en) 2016-01-13

Family

ID=45044505

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11788050.0A Active EP2652123B1 (en) 2010-12-16 2011-11-18 Dry granulated cell culture media

Country Status (10)

Country Link
US (1) US9399757B2 (es)
EP (1) EP2652123B1 (es)
JP (1) JP5907988B2 (es)
KR (1) KR101899175B1 (es)
CN (2) CN103261404B (es)
BR (1) BR112013015213B1 (es)
CA (1) CA2821799C (es)
ES (1) ES2565349T3 (es)
MX (1) MX343113B (es)
WO (1) WO2012079679A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017030B1 (fr) * 2014-02-05 2017-09-01 Cathy Lopez Produit nutritionnel a base d'insectes
KR101617858B1 (ko) * 2014-07-07 2016-05-04 유한책임회사 암브로티아 습식 과립화된 세포 배양 배지 및 그 제조방법
KR20160019331A (ko) 2014-08-11 2016-02-19 주식회사 포어링크 자동차 보험료 산출 시스템
US10822584B2 (en) 2015-12-17 2020-11-03 Life Technologies Corporation Pellets used in cell culture and methods of making thereof
CA3068685A1 (en) * 2017-06-27 2019-01-03 Ajinomoto Co., Inc. Riboflavin derivative-containing medium
JP2019187404A (ja) * 2018-04-25 2019-10-31 八千代 原 培地の打錠方法
WO2020218584A1 (ja) * 2019-04-26 2020-10-29 味の素株式会社 細胞培養用組成物
EP4031648A1 (en) * 2019-09-19 2022-07-27 Life Technologies Corporation Cell culture media tablets and methods of manufacture
KR102484756B1 (ko) * 2020-11-13 2023-01-06 한국생산기술연구원 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944224A (en) 1959-12-02 1963-12-11 Corn Products Co Compacted starch and method for producing same
DE2220065A1 (de) 1972-04-24 1973-11-08 Microbiological Ass Inc Naehrboeden
US4075067A (en) 1975-02-25 1978-02-21 Alcan Research And Development Limited Production of aluminium
US4308288A (en) 1979-12-07 1981-12-29 Morinaga & Company, Limited Method of producing granular cocoa
EP0331222A2 (en) 1988-03-02 1989-09-06 Unilever N.V. Granular beverage material for tea, coffee or cocoa, and method of its preparation
WO2000008092A1 (en) 1998-08-02 2000-02-17 The B.F. Goodrich Company Controlled release polyacrylic acid granules and a process for preparing the same
WO2001060842A2 (en) 2000-02-16 2001-08-23 The Nutrasweet Company PROCESS FOR MAKING GRANULATED N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER
US6383810B2 (en) 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
WO2002036735A2 (en) 2000-11-06 2002-05-10 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
EP1027389B1 (de) 1997-10-31 2002-09-18 E.I. Dupont de Nemours and Company, Inc. Kontinuierliches verfahren zur wiederverwendung von pulverlackabfällen und die erhaltenen pulverlacke
WO2003086362A2 (en) 2002-04-15 2003-10-23 Ranbaxy Laboratories Limited Method of stabilizing bupropion hydrochloride tablets
WO2005048731A2 (en) 2003-11-17 2005-06-02 Cargill, Incorporated Lecithin-containing granular compositions and methods of their preparation
US20060042338A1 (en) 2004-08-31 2006-03-02 Cargill, Incorporated Method for producing a fertilizer with micronutrients
WO2006095337A2 (en) 2005-03-07 2006-09-14 Bromine Compounds Ltd. A process for the preparation of melamine cyanurate
WO2006112958A2 (en) 2005-03-03 2006-10-26 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
US20070216068A1 (en) 2006-03-16 2007-09-20 Neumann Eberhard W Process and apparatus for handling synthetic gypsum
US20080213360A1 (en) 2006-10-27 2008-09-04 Fmc Corporation Dry granulation binders, products, and use thereof
US20080254119A1 (en) 2007-04-16 2008-10-16 Wyeth Imbedded liquid lubricants for tableting
US20090253593A1 (en) 2005-09-26 2009-10-08 Bromine Compounds Ltd. Solid product for preparing a drilling fluid
WO2010003641A1 (en) 2008-07-08 2010-01-14 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0257175A (ja) * 1988-08-19 1990-02-26 Morinaga & Co Ltd 成形培地及びその製造法
JP2729712B2 (ja) * 1991-04-23 1998-03-18 寳酒造株式会社 機能性ポリペプチド
CN1079435C (zh) * 1998-01-21 2002-02-20 鞠秋艳 一种人红细胞培养基的制备方法
EP2172227A3 (en) * 1998-06-30 2011-01-19 Life Technologies Corporation Methods for reducing adventitious agents or toxins in a sample and cell culture reagents produced thereby
WO2008074015A1 (en) * 2006-12-14 2008-06-19 Church & Dwight Co., Inc. Water soluble media containing anti-microbial agents
JP5543704B2 (ja) * 2007-10-16 2014-07-09 サッポロビール株式会社 粉末培地

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944224A (en) 1959-12-02 1963-12-11 Corn Products Co Compacted starch and method for producing same
DE2220065A1 (de) 1972-04-24 1973-11-08 Microbiological Ass Inc Naehrboeden
US4075067A (en) 1975-02-25 1978-02-21 Alcan Research And Development Limited Production of aluminium
US4308288A (en) 1979-12-07 1981-12-29 Morinaga & Company, Limited Method of producing granular cocoa
EP0331222A2 (en) 1988-03-02 1989-09-06 Unilever N.V. Granular beverage material for tea, coffee or cocoa, and method of its preparation
US6383810B2 (en) 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
EP1027389B1 (de) 1997-10-31 2002-09-18 E.I. Dupont de Nemours and Company, Inc. Kontinuierliches verfahren zur wiederverwendung von pulverlackabfällen und die erhaltenen pulverlacke
WO2000008092A1 (en) 1998-08-02 2000-02-17 The B.F. Goodrich Company Controlled release polyacrylic acid granules and a process for preparing the same
WO2001060842A2 (en) 2000-02-16 2001-08-23 The Nutrasweet Company PROCESS FOR MAKING GRANULATED N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER
WO2002036735A2 (en) 2000-11-06 2002-05-10 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
WO2003086362A2 (en) 2002-04-15 2003-10-23 Ranbaxy Laboratories Limited Method of stabilizing bupropion hydrochloride tablets
WO2005048731A2 (en) 2003-11-17 2005-06-02 Cargill, Incorporated Lecithin-containing granular compositions and methods of their preparation
US20060042338A1 (en) 2004-08-31 2006-03-02 Cargill, Incorporated Method for producing a fertilizer with micronutrients
WO2006112958A2 (en) 2005-03-03 2006-10-26 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
WO2006095337A2 (en) 2005-03-07 2006-09-14 Bromine Compounds Ltd. A process for the preparation of melamine cyanurate
US20090253593A1 (en) 2005-09-26 2009-10-08 Bromine Compounds Ltd. Solid product for preparing a drilling fluid
US20070216068A1 (en) 2006-03-16 2007-09-20 Neumann Eberhard W Process and apparatus for handling synthetic gypsum
US20080213360A1 (en) 2006-10-27 2008-09-04 Fmc Corporation Dry granulation binders, products, and use thereof
US20080254119A1 (en) 2007-04-16 2008-10-16 Wyeth Imbedded liquid lubricants for tableting
WO2008130883A1 (en) 2007-04-16 2008-10-30 Wyeth Embedded liquid lubricants for tableting
WO2010003641A1 (en) 2008-07-08 2010-01-14 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Invitrogen offers New GibcoTM Advanced Granulation Technology (AGT", INTRODUC- ING A NOVEL FORMAT OF DRY CELL MEDIA FOR BIOPRODUCTION;, 1 June 2001 (2001-06-01)
FIKE, R. ET AL.: "Advanced Granulation Tech- nology (AGT?) - An alternate format for serum-free, chemically-defined and protein- free cell culture media;", CYTOTECHNOLOGY, vol. 36, 2001, pages 33 - 39, XP019236700
KLEINEBUDDE, P.: "Roll compaction/dry granu- lation: pharmaceutical applications;", EURO- PEAN JOURNAL OF PHARMACEUTICS AND BIO- PHARMACEUTICS, vol. 58, 2004, pages 317 - 326, XP004526315
MILLER, R.W.: "Roller Compaction Technolo- gy", HANDBOOK OF PHAR- MACEUTICAL GRANULATION TECHNOLOGY, 2005, pages 159 - 190
WENNERSTRUM, S: "Ten things you need to consider when choosing and installing a roller press system;", POWDER AND BULK ENGI- NEERING, February 2000 (2000-02-01), XP055313717
WIBOWO, C. ET AL.: "Synthesis of Bulk Solids Processing Systems", AICHE JOURNAL 45, August 1999 (1999-08-01), XP055313718

Also Published As

Publication number Publication date
MX343113B (es) 2016-10-25
US20130267027A1 (en) 2013-10-10
KR20140032370A (ko) 2014-03-14
MX2013005140A (es) 2013-07-03
CN103261404A (zh) 2013-08-21
KR101899175B1 (ko) 2018-09-14
ES2565349T3 (es) 2016-04-04
JP2013545484A (ja) 2013-12-26
JP5907988B2 (ja) 2016-04-26
BR112013015213A2 (pt) 2021-05-04
EP2652123A1 (en) 2013-10-23
CA2821799C (en) 2020-01-14
CN103261404B (zh) 2017-06-09
US9399757B2 (en) 2016-07-26
BR112013015213B1 (pt) 2021-11-03
CA2821799A1 (en) 2012-06-21
CN105274047A (zh) 2016-01-27
CN105274047B (zh) 2019-03-01
WO2012079679A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
EP2652123B1 (en) Dry granulated cell culture media
EP3230436B1 (en) Cell culture media
EP3019594B1 (en) Cell culture media
KR102062518B1 (ko) 세포 배양 배지의 제조 방법
US20220204918A1 (en) Cell culture media comprising keto acids
EP3230437B1 (en) Process for improving the solubility of cell culture media
US8944352B2 (en) Process and apparatus for producing cell culture media
US20190256819A1 (en) Process for improving the dissolution behaviour of components in aqueous solutions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140519

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150709

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 770534

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011022691

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2565349

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160404

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 770534

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160414

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160513

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160513

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602011022691

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

26 Opposition filed

Opponent name: HUETTERMANN, ALOYS

Effective date: 20161012

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: HUETTERMANN, ALOYS

Effective date: 20161012

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161130

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161118

PLCK Communication despatched that opposition was rejected

Free format text: ORIGINAL CODE: EPIDOSNREJ1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20111118

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161118

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: MERCK PATENT GMBH

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

REG Reference to a national code

Ref country code: DE

Ref legal event code: R100

Ref document number: 602011022691

Country of ref document: DE

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

27O Opposition rejected

Effective date: 20221031

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231201

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231010

Year of fee payment: 13

Ref country code: DE

Payment date: 20230926

Year of fee payment: 13

Ref country code: CH

Payment date: 20231202

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20231016

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240926

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240909

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240917

Year of fee payment: 14